KRAS Status is Related to Histological Phenotype in Gastric Cancer: Results from a Large Multicentre Study

Overview

Journal Gastric Cancer

Specialties Gastroenterology
Oncology

Date 2019 May 22

PMID 31111275

Citations 15

Authors

Lindsay C Hewitt

Yuichi Saito

Tan Wang

Yoko Matsuda

Jan Oosting

Arnaldo N S Silva

Hayley L Slaney

Veerle Melotte

Gordon Hutchins

Patrick Tan

Takaki Yoshikawa

Tomio Arai

Heike I Grabsch

Affiliations

Soon will be listed here.

Abstract

Background: Gastric cancer (GC) is histologically a very heterogeneous disease, and the temporal development of different histological phenotypes remains unclear. Recent studies in lung and ovarian cancer suggest that KRAS activation (KRASact) can influence histological phenotype. KRASact likely results from KRAS mutation (KRASmut) or KRAS amplification (KRASamp). The aim of the study was to investigate whether KRASmut and/or KRASamp are related to the histological phenotype in GC.

Methods: Digitized haematoxylin/eosin-stained slides from 1282 GC resection specimens were classified according to Japanese Gastric Cancer Association (JGCA) and the Lauren classification by at least two observers. The relationship between KRAS status, predominant histological phenotype and clinicopathological variables was assessed.

Results: KRASmut and KRASamp were found in 68 (5%) and 47 (7%) GCs, respectively. Within the KRASmut and KRASamp cases, the most frequent GC histological phenotype was moderately differentiated tubular 2 (tub2) type (KRASmut: n = 27, 40%; KRASamp: n = 21, 46%) or intestinal type (KRASmut: n = 41, 61%; KRASamp: n = 23, 50%). Comparing individual histological subtypes, mucinous carcinoma displayed the highest frequency of KRASmut (JGCA: n = 6, 12%, p = 0.012; Lauren: n = 6, 12%, p = 0.013), and KRASamp was more frequently found in poorly differentiated solid type (n = 12, 10%, p = 0.267) or indeterminate type (n = 12, 10%, p = 0.480) GC. 724 GCs (57%) had intratumour morphological heterogeneity.

Conclusions: This is the largest GC study investigating KRAS status and histological phenotype. We identified a relationship between KRASmut and mucinous phenotype. The high level of intratumour morphological heterogeneity could reflect KRASmut heterogeneity, which may explain the failure of anti-EGFR therapy in GC.

Citing Articles

The relationship between the gastric cancer microbiome and clinicopathological factors: a metagenomic investigation from the 100,000 genomes project and The Cancer Genome Atlas.

Booth M, Wood H, Travis M, Quirke P, Grabsch H Gastric Cancer. 2025; .

PMID: 39961991 DOI: 10.1007/s10120-025-01588-9.

The potential contribution of aberrant cathepsin K expression to gastric cancer pathogenesis.

Feng Z, Gao L, Lu Y, He X, Xie J Discov Oncol. 2024; 15(1):218.

PMID: 38856944 PMC: 11164852. DOI: 10.1007/s12672-023-00814-z.

The Combination of Afatinib With Dasatinib or Miransertib Results in Synergistic Growth Inhibition of Stomach Cancer Cells.

Al-Janaby T, Nahi N, Seddon A, Bagwan I, Khelwatty S, Modjtahedi H World J Oncol. 2024; 15(2):192-208.

PMID: 38545471 PMC: 10965263. DOI: 10.14740/wjon1769.

Generalizable biomarker prediction from cancer pathology slides with self-supervised deep learning: A retrospective multi-centric study.

Niehues J, Quirke P, West N, Grabsch H, van Treeck M, Schirris Y Cell Rep Med. 2023; 4(4):100980.

PMID: 36958327 PMC: 10140458. DOI: 10.1016/j.xcrm.2023.100980.

Development of alternative herbals remedy for gastric cancer based on transcriptomic analysis of immune infiltration and ferroptosis.

Li M, Tao J, Qian R, Jiang F, Song Y, Zeng Z Front Genet. 2023; 14:1086368.

PMID: 36936437 PMC: 10020191. DOI: 10.3389/fgene.2023.1086368.

References

Coudray N, Ocampo P, Sakellaropoulos T, Narula N, Snuderl M, Fenyo D . Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat Med. 2018; 24(10):1559-1567. PMC: 9847512. DOI: 10.1038/s41591-018-0177-5. View

Arai T, Matsuda Y, Aida J, Takubo K, Ishiwata T . Solid-type poorly differentiated adenocarcinoma of the stomach: clinicopathological and molecular characteristics and histogenesis. Gastric Cancer. 2018; 22(2):314-322. DOI: 10.1007/s10120-018-0862-6. View

Esemuede I, Forslund A, Khan S, Qin L, Gimbel M, Nash G . Improved testing for microsatellite instability in colorectal cancer using a simplified 3-marker assay. Ann Surg Oncol. 2010; 17(12):3370-8. PMC: 3269820. DOI: 10.1245/s10434-010-1147-4. View

. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011; 14(2):101-12. DOI: 10.1007/s10120-011-0041-5. View

Cristescu R, Lee J, Nebozhyn M, Kim K, Ting J, Wong S . Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015; 21(5):449-56. DOI: 10.1038/nm.3850. View

Junttila M, de Sauvage F . Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013; 501(7467):346-54. DOI: 10.1038/nature12626. View

Hanemaaijer N, Sikkema-Raddatz B, van der Vries G, Dijkhuizen T, Hordijk R, van Essen A . Practical guidelines for interpreting copy number gains detected by high-resolution array in routine diagnostics. Eur J Hum Genet. 2011; 20(2):161-5. PMC: 3260923. DOI: 10.1038/ejhg.2011.174. View

Er T, Chen C, Bujanda L, Herreros-Villanueva M . Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patients. Biomed Res Int. 2014; 2014:591867. PMC: 4086227. DOI: 10.1155/2014/591867. View

Jayson G, Kohn E, Kitchener H, Ledermann J . Ovarian cancer. Lancet. 2014; 384(9951):1376-88. DOI: 10.1016/S0140-6736(13)62146-7. View

10.

Zhao W, Chan T, Chu K, Chan A, Stratton M, Yuen S . Mutations of BRAF and KRAS in gastric cancer and their association with microsatellite instability. Int J Cancer. 2003; 108(1):167-9. DOI: 10.1002/ijc.11553. View

11.

Khan M, Loree J, Advani S, Ning J, Li W, Pereira A . Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Clin Colorectal Cancer. 2018; 17(4):e699-e709. PMC: 6588353. DOI: 10.1016/j.clcc.2018.07.005. View

12.

Matsunaga M, Kaneta T, Miwa K, Ichikawa W, Fujita K, Nagashima F . A comparison of four methods for detecting mutations in formalin-fixed specimens from metastatic colorectal cancer patients. Oncol Lett. 2016; 12(1):150-156. PMC: 4906624. DOI: 10.3892/ol.2016.4576. View

13.

Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T . Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene. 1990; 5(7):1037-43. View

14.

Singh H, Longo D, Chabner B . Improving Prospects for Targeting RAS. J Clin Oncol. 2015; 33(31):3650-9. DOI: 10.1200/JCO.2015.62.1052. View

15.

LAUREN P . THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand. 1965; 64:31-49. DOI: 10.1111/apm.1965.64.1.31. View

16.

de la Chapelle A, Hampel H . Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol. 2010; 28(20):3380-7. PMC: 2903331. DOI: 10.1200/JCO.2009.27.0652. View

17.

Kinoshita H, Hayakawa Y, Konishi M, Hata M, Tsuboi M, Hayata Y . Three types of metaplasia model through Kras activation, Pten deletion, or Cdh1 deletion in the gastric epithelium. J Pathol. 2018; 247(1):35-47. DOI: 10.1002/path.5163. View

18.

Ooi A, Inokuchi M, Harada S, Inazawa J, Tajiri R, Kitamura S . Gene amplification of ESR1 in breast cancers--fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study. J Pathol. 2011; 227(1):8-16. DOI: 10.1002/path.3974. View

19.

Bunyan D, Eccles D, Sillibourne J, Wilkins E, Thomas N, Shea-Simonds J . Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. Br J Cancer. 2004; 91(6):1155-9. PMC: 2747696. DOI: 10.1038/sj.bjc.6602121. View

20.

Carvalho P, Guimaraes C, Cardoso A, Mendonca S, Costa A, Oliveira M . KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment. Cancer Res. 2017; 78(1):7-14. DOI: 10.1158/0008-5472.CAN-17-2084. View